Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines

por Flocke, Lea S., Trondl, Robert, Jakupec, Michael A., Keppler, Bernhard K.
Publicado 2016

NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer

por Trondl, Robert, Heffeter, Petra, Jakupec, Michael A, Berger, Walter, Keppler, Bernhard K
Publicado 2012

α-N-Heterocyclic thiosemicarbazones induce ER stress-mediated CHOP activation

por Trondl, Robert, Kowol, Christian R, Arion, Vladimir B, Jakupec, Michael A, Keppler, Bernhard K
Publicado 2010

Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy

por Wilfinger, Nastasia, Austin, Shane, Scheiber-Mojdehkar, Barbara, Berger, Walter, Reipert, Siegfried, Praschberger, Monika, Paur, Jakob, Trondl, Robert, Keppler, Bernhard K., Zielinski, Christoph C., Nowikovsky, Karin
Publicado 2015